
Seul Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10011066/publications.pdf Version: 2024-02-01



SEULLEE

#	Article	IF	CITATIONS
1	Post-translational modification of OCT4 in breast cancer tumorigenesis. Cell Death and Differentiation, 2018, 25, 1781-1795.	11.2	65
2	Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer. European Journal of Cancer, 2021, 153, 179-189.	2.8	16
3	Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Reports, 2020, 53, 533-538.	2.4	11
4	Chest CT abnormalities in COVID-19: a systematic review. International Journal of Medical Sciences, 2021, 18, 3395-3402.	2.5	9
5	Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor. Yonsei Medical Journal, 2022, 63, 42.	2.2	7
6	Incorporation of SKI-C-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity. Frontiers in Oncology, 2022, 12, 821391.	2.8	6
7	Abstract 1826: Comprehensive preclinical study on Gl-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target. Cancer Research, 2021, 81, 1826-1826.	0.9	5
8	The Association of Maternal Accompaniment at Family Dinners and Depressive Symptoms of Korean Adolescents. International Journal of Environmental Research and Public Health, 2020, 17, 1743.	2.6	1
9	A Case of Idiopathic Hypomagnesemia with Hypocalcemia Presenting as Generalized Tonic-Clonic Seizure. Journal of Korean Society of Pediatric Endocrinology, 2011, 16, 193.	0.2	0
10	572â€Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkineâ"¢ potentiates anti-cancer effects in preclinical cancer models. , 2020, , .		0
11	Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice. Cancer Research, 2022, 82, 5481-5481.	0.9	0